Genenta Science
GNTA
15 hedge funds and large institutions have $4.04M invested in Genenta Science in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
150% more funds holding
Funds holding: 6 → 15 (+9)
129% more capital invested
Capital invested by funds: $1.77M → $4.04M (+$2.28M)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
8.56% more ownership
Funds ownership: 3.02% → 11.58% (+8.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.51M |
| 2 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$762K |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$758K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$518K |
| 5 |
Morgan Stanley
New York
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$782 |
GNTA Hedge Fund Activity: Q4 2025 in Review
15 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Genenta Science (GNTA) for Q4 2025, worth a combined $4.04M — up 129% from $1.77M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GNTA positions and 0 closed out — a net gain of 9 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $1.51M. The largest seller was National Bank of Canada, cutting an estimated $782.
- 15 institutional investors held Genenta Science (GNTA) as of Q4 2025, up from 6 in Q3 2025.
- Funds reported $4.04M of Genenta Science stock for Q4 2025, up 129% quarter-over-quarter.
- 9 funds opened new Genenta Science positions in Q4 2025 and 0 closed out, a net change of +9 holders.
- The largest Genenta Science buyer in Q4 2025 was Citadel Advisors, an estimated $1.51M added.
- The largest Genenta Science seller in Q4 2025 was National Bank of Canada, an estimated $782 sold.
Based on aggregated 13F filings for Q4 2025.